Common Contracts
8 similar Purchase Agreement contracts by LDR Holding Corp, Inovio Pharmaceuticals, Inc., Aveo Pharmaceuticals Inc, others
30,000,000 Shares AVEO PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • March 29th, 2017 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York
AVEO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom Piper Jaffray & Co. is acting as representative (the “Representative”), an aggregate of 30,000,000 authorized but unissued shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 4,500,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 2 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
6,200,000 Shares VERICEL CORPORATION Common Stock PURCHASE AGREEMENTPurchase Agreement • December 16th, 2016 • Vericel Corp • Biological products, (no disgnostic substances) • New York
PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402
9,500,000 Shares INOVIO PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • April 30th, 2015 • Inovio Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus • New York
Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as representatives (the “Representatives”), an aggregate of 9,500,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,425,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 2 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
5,125,000 Shares MEDGENICS, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • December 1st, 2014 • Medgenics, Inc. • Biological products, (no disgnostic substances) • New York
Medgenics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom Piper Jaffray & Co. is acting as representative (the “Representative”), an aggregate of 5,125,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 768,750 additional shares of Common Stock, on the terms and for the purposes set forth in Section 2 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
3,972,089 Shares LDR Holding Corporation Common Stock PURCHASE AGREEMENTPurchase Agreement • May 16th, 2014 • LDR Holding Corp • Surgical & medical instruments & apparatus • New York
LDR Holding Corporation, a Delaware corporation (the “Company”), and the stockholders of the Company listed in Schedule I hereto (the “Selling Stockholders”) severally propose to sell to the several Underwriters named in Schedule II hereto (the “Underwriters”) an aggregate of 3,972,089 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 1,300,000 authorized but unissued shares of Common Stock to be issued and sold by the Company and 2,672,089 outstanding shares of Common Stock to be sold by the Selling Stockholders. The Company and the Selling Stockholders have also granted to the several Underwriters an option to purchase up to 195,000 and 400,813 additional shares of Common Stock, respectively, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Sec
— ] Shares LDR Holding Corporation Common Stock PURCHASE AGREEMENTPurchase Agreement • May 12th, 2014 • LDR Holding Corp • Surgical & medical instruments & apparatus • New York
— ] Shares LDR Holding Corporation Common Stock PURCHASE AGREEMENTPurchase Agreement • April 11th, 2014 • LDR Holding Corp • Surgical & medical instruments & apparatus • New York
18,966,000 Shares1 INOVIO PHARMACEUTICALS, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • February 27th, 2014 • Inovio Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus • New York
Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as representatives (the “Representatives”), an aggregate of 18,966,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 2,844,900 additional shares of Common Stock, on the terms and for the purposes set forth in Section 2 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement (this “Agreement”) are herein collectively called the “Securities.”
